News & Updates

First-line treatment with cemiplimab, either as monotherapy or in combination with platinum-based chemotherapy, provides clinical benefits to patients with unresectable locally advanced nonsmall cell lung cancer (NSCLC) who are not candidates for definitive concurrent chemoradiation, as shown by long-term follow-up data from EMPOWER-Lung studies.

Use of psychedelic drugs appears to have some benefits in reducing anxiety and depressive symptoms among patients with cancer or other life-threatening diseases, reports a study.

Treatment with liposomal irinotecan in adults with relapsed small cell lung cancer (SCLC) achieves similar overall survival (OS) when compared with topotecan, but the former is associated with a higher overall response rate (ORR), according to the results of RESILIENT, randomized, open-label phase III trial.

Patients undergoing more extensive lymph node sampling during surgery for a suspected malignant paediatric renal tumour do not appear to have a higher likelihood of experiencing clinically significant complications, reveals a study.

In the 3-year analysis of the phase III CheckMate 816 trial, neoadjuvant nivolumab plus platinum doublet chemotherapy (nivo-chemo) continued to provide durable benefit for individuals with resectable non-small-cell lung cancer (NSCLC).